Komipharm International

Komipharm, founded in 1972, is an animal vaccine and pharmaceutical specialist with production bases in Siheung, Gyeonggi Province, and Yesan County, South Chungcheong Province.

Its core revenue comes from sales of animal vaccines and veterinary medicines, including antibiotics and disinfectants, for swine, cattle, and poultry, alongside diagnostic services such as pathology, serology, and bacteriology testing.

In recent years, the company's growth axis has shifted toward the African swine fever (ASF) vaccine 'PRO-VAC ASF,' developed since 2021 based on the attenuated live vaccine strain ASFV-G-ΔI177L/ΔLVR licensed from the US Department of Agriculture (USDA).

In parallel, the human pharmaceutical division is developing the anticancer and cancer-pain drug candidate 'Kominox (PAX-1),' with trials underway in Korea, Australia, and Taiwan targeting glioblastoma and brain-metastatic lung cancer.

The largest shareholder is Chairman and CEO Yang Kyung-hoon, holding roughly 31.21% of shares, with the company operating under a co-CEO structure alongside Moon Sung-chul.

In the ASF vaccine space, domestic peer Choong Ang Vaccine Laboratories is pursuing a similar goal, creating a competitive landscape; both companies held parallel symposia at the 2026 International Pig Veterinary Society (IPVS) congress to present commercialization strategies.

Overall, the company can be viewed as layering vaccine and new-drug pipeline growth options on top of a stable animal-health cash-generating base.

In 2025, consolidated revenue was KRW 52.47 billion, down from KRW 58.78 billion in 2024, while operating profit fell sharply to KRW 1.96 billion (3.7% operating margin) from KRW 6.19 billion (10.5% margin) in 2024.

Net income attributable to owners swung from a profit of KRW 13.11 billion in 2024 to a loss of KRW 7.21 billion in 2025, largely attributable to non-operating factors including derivative valuation gains/losses tied to convertible bonds and human drug development expenses.

In 2023, the company posted an operating loss of KRW 6.27 billion (-14.7% margin) and a net loss attributable to owners of KRW 3.98 billion, and in 2022 it recorded an operating loss of KRW 3.80 billion and a net loss of KRW 6.51 billion, making 2024 the only profitable year among the past four fiscal years.

On a quarterly basis, Q2 2025 revenue was KRW 13.68 billion with operating profit of KRW 1.63 billion, yet the net loss attributable to owners reached KRW 3.20 billion; Q3 2025 slowed sharply to KRW 12.48 billion in revenue and KRW 0.066 billion in operating profit, before Q4 2025 deteriorated again with an operating loss of KRW 0.24 billion and a net loss of KRW 3.91 billion.

The trend reversed in Q1 2026, with revenue of KRW 11.94 billion, operating profit of KRW 0.30 billion, and net income of KRW 0.86 billion, followed by Q2 2026 revenue of KRW 16.70 billion, operating profit of KRW 1.64 billion, and net income of KRW 0.62 billion, marking two consecutive profitable quarters.

Over the trailing four quarters (Q3 2025 through Q2 2026), the cumulative net loss attributable to owners was approximately KRW 2.58 billion, underscoring the continued volatility of quarterly results.

Operating cash flow also weakened to negative KRW 0.62 billion in 2025 from positive KRW 8.85 billion in 2024, reflecting investment in vaccine production facilities and new drug development spending.

The global swine industry has faced a prolonged biosecurity crisis since African swine fever (ASF) first emerged in China in 2018, with a total of 20 countries reporting outbreaks as of July 2026.

The absence of a commercially approved preventive vaccine remains a market gap, representing a meaningful opportunity for companies developing effective vaccines.

Domestically, Komipharm and Choong Ang Vaccine Laboratories are competing to commercialize ASF vaccines that have each secured export-only product approval, with both targeting Southeast Asian countries such as Vietnam and the Philippines as priority markets.

Notably, a highly transmissible and lethal 'hybrid' recombinant strain (genotype I/II) has been spreading in Vietnam and elsewhere, making resistance to this variant an emerging differentiator in vaccine competitiveness.

The Philippine government has issued a presidential directive stating it will adopt even trial-stage vaccines once safety and efficacy are confirmed, reflecting a relatively favorable regulatory environment for commercialization.

In the human pharmaceutical segment, there remains unmet need in intractable brain cancers such as glioblastoma for drug candidates with high blood-brain barrier penetration, though the development cycle is long, as commercialization visibility typically requires reaching multinational Phase 3 trials.

The company expects the Philippines field trial to be completed within Q4 2026, with the process structured so that submission of a results report leads to product-use approval.

Starting in August, it plans to sequentially pursue overseas product approvals in countries where preparations are complete, while simultaneously building out production and quality-control systems for global supply.

The KRW 12 billion in convertible bonds raised for production facility expansion is scheduled to be deployed in phases from October 2025 through the end of 2026, implying continued capital investment through year-end.

An oral ASF vaccine candidate has also had additional research results published in an international journal, with the company stating it intends to pursue commercialization of both the injectable and oral formulations in parallel.

CEO Moon Sung-chul stated in an interview that "Komipharm has now moved beyond the R&D stage and entered a phase of preparing for actual global commercialization." In the human pharmaceutical segment, a multinational Phase 3 trial for the cancer-pain treatment PAX-1 is reportedly planned, though this should be viewed as a separate option with a long development cycle.

Multiple variables remain unresolved, including the finalization of an overseas production base (whether contract manufacturing or use of local facilities) and the timing of country-by-country product approvals, so the schedule may remain fluid.